相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
Odette S. Reifsnider et al.
DIABETES OBESITY & METABOLISM (2022)
Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States
Odette Reifsnider et al.
DIABETES OBESITY & METABOLISM (2021)
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
George Gourzoulidis et al.
CLINICAL DRUG INVESTIGATION (2021)
The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Lars H. Ehlers et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)
Effectiveness and Safety of Empagliflozin in Routine Care in Europe and East Asia: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Avraham Karasik et al.
DIABETES (2021)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study
Lars Bernfort et al.
DIABETES THERAPY (2020)
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
Michael Willis et al.
PHARMACOECONOMICS (2020)
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
Mafalda Ramos et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
Emelie Andersson et al.
DIABETOLOGIA (2020)
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
Lars Bernfort et al.
DIABETES THERAPY (2020)
Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Bjorn Eliasson et al.
DIABETES THERAPY (2019)
Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial
A. Kansal et al.
DIABETIC MEDICINE (2019)
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study
Anna Norhammar et al.
DIABETES OBESITY & METABOLISM (2019)
Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review
Michael Willis et al.
DIABETES THERAPY (2019)
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Mafalda Ramos et al.
DIABETES THERAPY (2019)
Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors
Andre J. Scheen
CIRCULATION RESEARCH (2018)
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
George Gourzoulidis et al.
CLINICAL DRUG INVESTIGATION (2018)
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge
Andrew J. Palmer et al.
VALUE IN HEALTH (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
BUDGET IMPACT ANALYSIS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE
G. Gourzoulidis et al.
VALUE IN HEALTH (2017)
BUDGET IMPACT ANALYSIS OF EMPAGLIFLOZIN (JARDIANCE®) IN TYPE-2 DIABETES PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE SOUTH AFRICAN SETTING: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
J. Carapinha et al.
VALUE IN HEALTH (2017)
Multivariate Prediction Equations for HbA1c, Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling
Michael Willis et al.
VALUE IN HEALTH (2017)
Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease
Sergio Iannazzo et al.
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT (2017)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IMPACT OF EMPAGLIFLOZIN (JARDIANCE) TO THE NHS: ESTIMATION OF BUDGET AND EVENT IMPACT BASED ON EMPA-REG OUTCOME DATA
I Daacke et al.
VALUE IN HEALTH (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Changes in Diabetes-Related Complications in the United States, 1990-2010
Edward W. Gregg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations
Adam Lundqvist et al.
PLOS ONE (2014)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
Review of Utility Values for Economic Modeling in Type 2 Diabetes
Amelie Beaudet et al.
VALUE IN HEALTH (2014)
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
A. J. Hayes et al.
DIABETOLOGIA (2013)
Towards Renewed Health Economic Simulation of Type 2 Diabetes: Risk Equations for First and Second Cardiovascular Events from Swedish Register Data
Aliasghar Ahmad Kiadaliri et al.
PLOS ONE (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
PHARMACOECONOMICS (2013)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes
AI Adler et al.
DIABETES CARE (2002)
分享论文
